[go: up one dir, main page]

WO1995015331B1 - SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF - Google Patents

SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF

Info

Publication number
WO1995015331B1
WO1995015331B1 PCT/US1994/013947 US9413947W WO9515331B1 WO 1995015331 B1 WO1995015331 B1 WO 1995015331B1 US 9413947 W US9413947 W US 9413947W WO 9515331 B1 WO9515331 B1 WO 9515331B1
Authority
WO
WIPO (PCT)
Prior art keywords
alk
agent
protein
lymphoma
npm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/013947
Other languages
French (fr)
Other versions
WO1995015331A1 (en
Filing date
Publication date
Priority claimed from US08/160,861 external-priority patent/US5529925A/en
Application filed filed Critical
Priority to AU15116/95A priority Critical patent/AU679833B2/en
Priority to JP7515804A priority patent/JPH09512161A/en
Priority to DE69433665T priority patent/DE69433665T3/en
Priority to EP95906601A priority patent/EP0731806B2/en
Publication of WO1995015331A1 publication Critical patent/WO1995015331A1/en
Publication of WO1995015331B1 publication Critical patent/WO1995015331B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

The present invention is based on the identification and sequence determination of fusion proteins generated by translocation which is present in t(2;5) lymphoma cells. Using either the amino acid or nucleic acid sequences of the fusion proteins disclosed herein, the present invention provides methods of detecting and treating t(2;5) lymphoma.

Claims

56
AMENDED CLAIMS
[received by the International Bureau on 24 May 1995 (24.05.95); original claim 41 amended; remaining claims unchanged (1 page)]
37. A method of identifying agents capable of binding to the NPM/ALK fusion protein comprising the steps of:
(a) contacting an agent with said NPM/ALK fusion protein; and
(b) determining whether said agent binds said NPM/ALK fusion protein.
38. An isolated agent capable of binding to the NPM/ALK fusion protein produced by the steps of:
(a) contacting an agent with said NPM/ALK fusion protein; and
(b) determining whether said agent binds said NPM/ALK fusion protein.
39. A method of identifying agents capable of binding to the ALK protein comprising the steps of:
(a) contacting an agent with said ALK protein; and
(b) determining whether said agent binds said ALK protein.
40. An isolated agent capable of binding of the ALK protein . produced by the steps of:
(a) contacting an agent with said ALK protein; and
(b) determining whether said agent binds said ALK protein.
41. The agent of claim 40 wherein said agent is a natural ligand of ALK.
42. A ribozyme which is capable of cleaving the mRNA encoding the ALK protein.
PCT/US1994/013947 1993-12-03 1994-12-05 SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF Ceased WO1995015331A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU15116/95A AU679833B2 (en) 1993-12-03 1994-12-05 Specific fusion nucleic acids and proteins present in human t(2;5) lymphoma, methods of detection and uses thereof
JP7515804A JPH09512161A (en) 1993-12-03 1994-12-05 Specific fusion nucleic acid and protein present in human T (2; 5) lymphoma, detection method and use thereof
DE69433665T DE69433665T3 (en) 1993-12-03 1994-12-05 SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS IN HUMAN T (2; 5) LYMPHOMES, METHOD FOR DETERMINING THEM AND USE THEREOF
EP95906601A EP0731806B2 (en) 1993-12-03 1994-12-05 SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,861 US5529925A (en) 1993-12-03 1993-12-03 Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US08/160,861 1993-12-03

Publications (2)

Publication Number Publication Date
WO1995015331A1 WO1995015331A1 (en) 1995-06-08
WO1995015331B1 true WO1995015331B1 (en) 1995-06-22

Family

ID=22578775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/013947 Ceased WO1995015331A1 (en) 1993-12-03 1994-12-05 SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF

Country Status (7)

Country Link
US (4) US5529925A (en)
EP (1) EP0731806B2 (en)
JP (1) JPH09512161A (en)
AU (1) AU679833B2 (en)
CA (1) CA2177957A1 (en)
DE (1) DE69433665T3 (en)
WO (1) WO1995015331A1 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US20030165931A1 (en) * 1998-03-11 2003-09-04 Bruno Tocque Qualitative differential screening
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
DE19610255B4 (en) * 1996-03-15 2004-11-04 Universität Heidelberg Process for the preparation of nucleic acid sequences and process for the detection of translocations between chromosomes
JP2001505428A (en) * 1996-12-06 2001-04-24 ニールズ パリスガード Detection of chromosomal abnormalities
US5994522A (en) * 1997-01-24 1999-11-30 Washington University BLNK proteins
US20030096255A1 (en) * 1997-02-19 2003-05-22 Felix Carolyn A. Methods and kits for analysis of chromosomal rearrangements associated with cancer
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
US6849400B1 (en) * 1997-07-23 2005-02-01 Gen-Probe Incorporated Methods for detecting and measuring spliced nucleic acids
WO1999057309A1 (en) * 1998-05-04 1999-11-11 Dako A/S Method and probes for the detection of chromosome aberrations
FR2798392B1 (en) * 1999-09-13 2005-07-15 Exonhit Therapeutics Sa GENETIC MARKERS OF TOXICITY, PREPARATION AND USES
FR2798673B1 (en) * 1999-09-16 2004-05-28 Exonhit Therapeutics Sa METHODS AND COMPOSITIONS FOR DETECTION OF PATHOLOGICAL EVENTS
US7528109B2 (en) * 2000-06-14 2009-05-05 Georgetown University Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
WO2002088309A2 (en) * 2001-04-27 2002-11-07 St. Jude Children's Research Hospital Fusion genes associated with acute megakaryoblastic leukemias
WO2003004645A1 (en) * 2001-07-03 2003-01-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of cancer involving the notch pathway
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7461843B1 (en) * 2002-08-23 2008-12-09 Elixir Gaming Technologies, Inc. Automatic card shuffler
CA2509902A1 (en) * 2002-12-13 2004-07-01 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
SI1454992T1 (en) * 2003-03-07 2006-10-31 Ist Naz Stud Cura Dei Tumori Anaplastic lymphoma kinase assay, reagents and compositions thereof
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
ITRM20040534A1 (en) * 2004-10-29 2005-01-29 Brunangelo Falini MUTANTS OF NUCLEOPHOSMINE PROTEIN (NPM), CORRESPONDING GENETIC SEQUENCES AND RELATED USES.
WO2007061684A1 (en) 2005-11-18 2007-05-31 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2450437B1 (en) * 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
AU2012201154B2 (en) * 2006-04-14 2012-09-13 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
AU2007246144B2 (en) * 2006-04-28 2012-12-06 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
JP5562640B2 (en) * 2007-04-13 2014-07-30 セル・シグナリング・テクノロジー・インコーポレイテツド Gene deletion and mutation ALK kinase in human solid tumors
WO2009045965A2 (en) * 2007-10-01 2009-04-09 The Trustees Of The University Of Pennsylvania Stat5a and its functional tumor suppressor analogs for treatment of malignancies expressing npm/alk and other oncogenic kinases
AU2009215168A1 (en) * 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
US8352194B1 (en) 2008-06-17 2013-01-08 University Of South Florida Method to identify cancer fusion genes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US20120208713A1 (en) * 2009-05-15 2012-08-16 Josh Nickols Methods and compositions relating to fusions of alk for diagnosing and treating cancer
CN102459648A (en) 2009-05-26 2012-05-16 奎斯特诊断投资公司 Methods for the detection of genetic disorders
JPWO2011043220A1 (en) * 2009-10-06 2013-03-04 富士レビオ株式会社 Measurement method of fusion gene
CN102713606A (en) * 2009-11-13 2012-10-03 无限制药股份有限公司 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2011079191A1 (en) 2009-12-23 2011-06-30 Quest Diagnostics Investments Incorporated Tmprss2 for the diagnosis of prostate disease
CA2796087A1 (en) * 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
AU2015201135B2 (en) * 2010-04-20 2017-02-02 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
JP2014534228A (en) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション Combination therapy of platinum-containing agents and HSP90 inhibitors
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
CN104994879A (en) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US9284594B2 (en) * 2013-07-23 2016-03-15 The Regents Of The University Of Michigan Compositions and methods relating to fusion protein biomarkers
US10160993B2 (en) * 2014-03-21 2018-12-25 Purdue Research Foundation Tyrosine kinase biosensors and methods of use
WO2015148494A1 (en) * 2014-03-25 2015-10-01 Quest Diagnostics Investments Incorporated Detection of gene fusions by intragenic differential expression (ide) using average cycle thresholds
TWI662039B (en) 2014-05-13 2019-06-11 瑞士商諾華公司 Compounds and compositions for inducing chondrogenesis
EP3155118A1 (en) * 2014-06-10 2017-04-19 Blueprint Medicines Corporation Pkn1 fusions
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
BR112017016973A2 (en) 2015-02-09 2018-04-03 Synta Pharmaceuticals Corp. hsp90 inhibitors and pd-1 inhibitors combination therapy for cancer treatment
WO2017065959A2 (en) * 2015-09-25 2017-04-20 Veracyte, Inc. Methods and compositions that utilize transcriptome sequencing data in machine learning-based classification
JP7048609B2 (en) * 2016-12-09 2022-04-05 ボリアル ジェノミクス， インコーポレイテッド Linked ligation
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
WO1991005064A1 (en) * 1989-10-02 1991-04-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A sensitive method for measurement of chimeric transcripts of dna containing translocations
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

Similar Documents

Publication Publication Date Title
WO1995015331B1 (en) SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF
CA2286304A1 (en) Pca3, pca3 genes, and methods of use
NL300153I1 (en) Factor VIIIC coding DNA sequences and related DNA constructs.
WO1998049313A3 (en) Characterization of granulocytic ehrlichia and methods of use
EP2048505A3 (en) Method for early recognition of the seroconversion of an antibody to hepatitis C
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
CA2234416A1 (en) Immunochemical determination of multivalent analytes
WO1998057984A3 (en) Torsin, torsin genes, and methods of use
AU2126400A (en) Detection of small molecules by use of a piezoelectric sensor
DE69902796D1 (en) METHOD FOR PURIFYING BIOMOLECULE OR PROTEIN COMPLEXES
WO1995013386A3 (en) Tyrosinase-activator protein fusion enzyme
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins
WO2003038116A3 (en) Salmonella virulence factors and uses thereof
ZA200007619B (en) New peptide fragments for protein purification.
WO2002021138A3 (en) The m30 gene family and the utilization thereof
GB2289125A (en) Methods of assaying data-repairing enzymes and their alkylated derivatives
WO2002072753A3 (en) Thymidylate synthase peptides that bind to thymidylate synthase messenger rna
WO1999023228B1 (en) Svph1-26 dna and polypeptides
Sokolovsky et al. Exhaustive Proteolysis of Derivatives of Lysozyme
EP1143011A3 (en) A method of detecting biologically active substances
WO1999050288A3 (en) Mammalian blood loss-induced gene, kd312
AU4624997A (en) Nematode proteins, dna sequences coding therefor, their specific antibodies and their use in identifying nematicidal active substances
CA2588614A1 (en) Method for analyzing the amount of intraabdominal adipose tissue
WO2002016574A3 (en) Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type